The table below shows Elicio Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
-
-
-
$2.30M
$28.31M
$2.88M
Cost of revenue
-
-
-
$0.00
$433.00K
$1.19M
Gross profit
-
-
-
-
-
-
R&D
$24.90M
$33.66M
$23.85M
$18.10M
$48.70M
$38.98M
SG&A
$12.81M
ELTX annual revenue (10-K history)
Elicio Therapeutics, Inc. reported annual revenue of $2.30M for fiscal year 2022. That is down 91.9% from $28.31M in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.